Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic...

Popoln opis

Bibliografske podrobnosti

Principais autores:	A. Spadaro, A. Scarno, A. Carboni, F.M. Perrotta, C. Catalano, E. Lubrano, G. Valesini
Format:	Artigo
Jezik:	Inglês
Izdano:	PAGEPress Publications 2013-07-01
Serija:	Reumatismo
Teme:	Certolizumab pegol, Axial spondyloarthritis, Magnetic resonance.
Online dostop:	http://www.reumatismo.org/index.php/reuma/article/view/660
Oznake:	Označite Brez oznak, prvi označite!